Press Release
« Back
Manhattan Pharmaceuticals Invited To Participate In Three Scientific Meetings On Obesity And Related Disorders
May 08, 2006
NEW YORK, NY MAY 8, 2006 - Manhattan Pharmaceuticals, Inc. (AMEX: MHA) announced today it has accepted invitations to participate in three upcoming scientific meetings focused on obesity and related disorders. The events are:
ENDO 2006 - The Endocrine Society's 88th Annual Meeting
Boston Convention & Exhibit Center, Boston, MA
June 24-27, 2006
Poster presentation titled: Effect of Chronic or Intermittent Oral Administration of Oleoyl-estrone on Food Intake, Body Weight and Body Composition in Normal Rats
2nd Annual Obesity Drug Development Summit
Ritz Carlton Hotel, Tyson's Corner, VA
July 27-28, 2006
Presentation titled: Oral Oleoyl-estrone - A Novel Small Molecule for the Treatment of Obesity
10th International Congress on Obesity
Sydney Convention & Exhibition Centre, Sydney, Australia
September 3-8, 2006
Poster presentation titled: Long-Term Treatment of Zucker Obese Rats with Oleoyl-estrone Decreases the Expression of Pro-inflammation Markers in White Adipose Tissue
Poster presentation titled: Pair-Feeding and Oleoyl-estrone Treatment of Lactating Rat Dams Affects Differentially the Growth of Their Offspring
About Manhattan Pharmaceuticals, Inc.
Manhattan Pharmaceuticals, Inc., a development stage pharmaceutical company, acquires and develops proprietary prescription drug candidates for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing OE, an orally administered novel therapeutic for weight loss. To meet the needs of other major, underserved medical markets while lowering development risks, Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for psoriasis and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures. (http://www.manhattanpharma.com)
